Kyverna Therapeutics, Inc. 8-K

What Happened

• Kyverna Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026 and filed an 8‑K on June 2, 2026 reporting the results. Of 60,530,293 shares outstanding as of the March 30, 2026 record date, 43,987,007 shares (about 73%) were represented, forming a quorum.
• Stockholders elected two Class II directors — Ian Clark and Christi Shaw — to serve until the 2029 annual meeting, and ratified the Audit Committee’s appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Shares outstanding (record date March 30, 2026): 60,530,293; shares represented at meeting: 43,987,007 (~73%).
• Director election votes:
  • Ian Clark: 31,505,902 For; 3,255,231 Withheld; 9,225,874 Broker Non‑Votes.
  • Christi Shaw: 34,528,865 For; 232,268 Withheld; 9,225,874 Broker Non‑Votes.
• Auditor ratification (BDO USA, P.C.):
  • For: 43,830,300; Against: 80,223; Abstentions: 76,484.
• The 8‑K was signed by Gregory Martini, Chief Financial Officer, on June 2, 2026.

Why It Matters

• Election of Ian Clark and Christi Shaw secures board continuity through 2029 and reflects shareholder approval of the current board slate. The vote totals and broker non‑votes show the level of shareholder support and participation.
• Ratifying BDO USA, P.C. ensures continuity of the company’s external audit relationship for 2026, an operational and governance detail investors monitor for financial reporting reliability.
• The filing is procedural and does not report financial results, leadership changes, mergers, or other material operational events; investors should look to future filings for updates on earnings, revenue, or strategic developments.